SWOG clinical trial number
S0353
Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Local Bladder
Activated
11/15/2006
Closed
10/15/2009
Participants
Research committees
Genitourinary Cancer
Treatment
Gemcitabine hydrochloride
Eligibility Criteria Expand/Collapse
Pts must have histologically proven, recurrent superficial TCC of the bladder Stage T1 Grade 2-4; Stage Tis; Stage Ta Grade 3-4; or multifocal (>2 lesions) Stage Ta any Grade. Must have rec'd at least 2 previous courses of intravesical BCG up to 3 yrs prior to reg. May have rec'd 1 course of chemo. Must not have rec'd gemcitabine prior to reg. Must have had a TURBT or bladder bx documenting above stage & grade at least 6 wks after last BCG and/or immunotherapy or at least 14 days after previous intravesical chemo and w/in 60 days prior to reg. All visible tumor must have been resected at last bx. Must have available representative slides for central path review. Must have had a negative upper tract imaging study w/in 2 yrs of reg w/no evidence of urethral or renal pelvis TCC. Must not have rec'd any prior pelvic RT nor planning to receive any concurrent RT. Must be offered opportunity to consent for specimen submission per Section 15. Must have Zubrod PS 0-2.
Publication Information Expand/Collapse
2016
PMid: PMID27376138 | PMC number: PMC4927845
2013
2012
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with superficial bladder cancer with recurrence following 2 prior courses of BCG
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase